Biotech · Private company · Cambridge, MA, US
Quiver Bioscience Inc.
Track this companyFree. Adds Quiver Bioscience Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards7
- Development of Nav channel targeting antisense oligonucleotides as chronic pain therapeutics using an integrated platform based on machine learning and optical electrophysiologyFiscal year 2026 · $2MNIH RePORTER 1UG3NS146009-01 · fetched Nov 12, 2026
- Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide NeurotoxicityFiscal year 2026 · $886KNIH RePORTER 5R44NS141534-02 · fetched Nov 12, 2026
- Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide NeurotoxicityFiscal year 2025 · $862.4KNIH RePORTER 1R44NS141534-01 · fetched Nov 12, 2026
- Ultra-High-Throughput Plate Reader for Drug Discovery Using All-Optical ElectrophysiologyFiscal year 2025 · $51.5KNIH RePORTER 3R44NS125689-07S1 · fetched Nov 12, 2026
- Functional drug fingerprinting with all-optical electrophysiologyFiscal year 2024 · $378.1KNIH RePORTER 5R44MH122052-05 · fetched Nov 12, 2026
- BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learningFiscal year 2024 · $1.3MNIH RePORTER 5R44MH135521-02 · fetched Nov 12, 2026
- Ultra-High-Throughput Plate Reader for Drug Discovery Using All-Optical ElectrophysiologyFiscal year 2024 · $251.1KNIH RePORTER 5R44NS125689-07 · fetched Nov 12, 2026